Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
393results about "Chemokines" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method for Purifying Antibodies
ActiveUS20130171095A1Increased serum half-lifeMinimize the possibilityFactor VIIPeptide/protein ingredientsIsoelectric pointAntibody
The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
Owner:XENCOR
Modular protein libraries and methods of preparation
InactiveUS6844161B2Efficient and high-yieldPeptide librariesChemokinesHigh-Throughput Screening AssaysProtein molecules
Novel proteins and protein libraries are disclosed. The proteins possess one or more functional protein modules from different parent protein molecules. The proteins and protein libraries are exemplified by the preparation of cross-over chemokines that contain various combinations of peptide segments derived from RANTES, SDS-1 and vMIP-I and to vMIP-II. The proteins and libraries are extremely pure and can be provided in non-limiting high yields suitable for diagnostic and high-throughput screening assays.
Owner:AMYLIN PHARMA INC
Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
InactiveUS20090226435A1Promote optimal activation of T cellConvenient treatmentChemokinesAntibody mimetics/scaffoldsTumor targetAbnormal tissue growth
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules consisting of a tumor targeting moiety fused with one or more costimulatory molecules / chemokines / cytokines.
Owner:KHARE SANJAY
Effectors of innate immunity
InactiveUS20070134261A1Reduce inflammationBlock/dampen inflammatory and/or septic responsesCompound screeningBacterial antigen ingredientsNucleotidePolynucleotide
The present invention provides a method of identifying agents that enhance innate immunity in a subject. The invention further provides a method of selectively supressing sepsis by suppressing expression of a proinflammatory gene while maintaining expression of an anti-inflammatory gene. Also provided are methods of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a peptide is described, methods of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response, and compounds and agents identified by the methods of the invention.
Owner:THE UNIV OF BRITISH COLUMBIA
Pd-1 antagonists and methods for treating infectious disease
InactiveUS20110159023A1Rapid induction of protectionRobust effector responseAntibacterial agentsOrganic active ingredientsDiseaseDendritic cell
Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and / or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by binding to and blocking PD-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of PD-1 such as PD-L1, thereby preventing (in whole or in part) the ligand from binding to PD-1 to deliver an inhibitory signal. The immune response can be modulated by providing antagonists which bind with different affinity (i.e., more or less as required), by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again (similar to what occurs with antigen elicitation using priming and boosting). In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.
Owner:AMPLIMMUNE
Transgenic mammal capable of facilitating production of donor-specific functional immunity
This invention provides for transgenic non-human mammalian models of human disease, methods of making such models as well as methods of using such models to assess efficacy of therapeutic and prophylaxis treatments, to assess the antigenic potential of compounds, and other uses.
Owner:GENENCOR INT INC
Treating inflammatory conditions
ActiveUS20110224645A1Increasing protein synthesisMinimize side-product formationPeptide/protein ingredientsOther blood circulation devicesDiseaseMedicine
An apheresis column loaded with a solid support comprises one or more chemokines, in particular biotinylated chemokines, immobilized directly or indirectly on the support, in particular on a support carrying streptavidin. Also disclosed are uses of the column and the support and a method of depleting cells, in particular leukocytes, from the peripheral blood of a person suffering from an inflammatory condition such as Inflammatory Bowel Disease (IBD).
Owner:TLA TARGETED IMMUNOTHERAPIES AB
Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
ActiveUS20080095758A1Increase concentrationObviates abilityNervous disorderPeptide/protein ingredientsDipeptidyl peptidaseMutant
The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
InactiveUS7157418B1Enhance and aid in survivalPrevent proliferationAntibacterial agentsBiocidePhagocyteDendritic cell
Conjugates containing as a ligand a chemokine receptor targeting agents, such as chemokines, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune effector cells, including leukocyte cell types, neutrophiles, macrophages, and eosinophils. The conjugates provided herein are used to lessen or inhibit these processes to prevent or at least lessen the resulting secondary effects. In particular, the conjugates are used to target toxins to receptors on secondary tissue damage-promoting cells. The ligand moiety can be selected to deliver the cell toxin to such secondary tissue damage-promoting cells as mononuclear phagocytes, leukocytes, natural killer cells, dendritic cells, and T and B lymphocytes, thereby suppressing the proliferation, migration, or physiological activity of such cells. Among preferred conjugates are fusion proteins having a chemokine, or a biologically active fragment thereof, as the ligand moiety linked to a cell toxin via a peptide linker of from 2 to about 60 amino acid residues.
Owner:OSPREY PHARMA USA INC
Antibodies to human IL-17F and other CTLA-8-related proteins
Owner:GENETICS INST INC
Use of immunopotentiating sequences for inducing immune response
InactiveUS6562800B1Boosting CTL productionIncrease in CTL productionNanotechGenetic material ingredientsCancer cellInfectious agent
The present invention provides an immunogenic composition comprising a DNA expression vector encoding both an immunopotentiating chemokine sequence as well as an immunogenic polypeptide sequence. Immunogenic polypeptide sequences are those of infectious agents or of cancerous cells. Also provided are methods of manufacturing various immunogenic compositions, and methods of using such compositions to treat cancer and infectious disease.
Owner:UNIV OF SOUTHERN CALIFORNIA
Method of treating sepsis with chemokines
InactiveUS6042821AImprove survivalReduce the possibilityAntibacterial agentsBiocideDimerAntiinfective agent
The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], gro alpha [SEQ ID NO:2], gro beta [SEQ ID NO: 3] or gro gamma [SEQ ID NO: 4] or multimers thereof, alone or in conjunction with an anti-infective agent. This invention also relates to a new gro beta dimer chemokine.
Owner:SMITHKLINE BECKMAN CORP
Lentiviral vector-mediated gene transfer and uses thereof
InactiveUS7122181B2Avoid failureInhibit neovascularizationBiocideSenses disorderGene transferOcular disease
The present invention provides lentiviral vectors that are useful in human gene therapy for inherited or acquired proliferative ocular disease. It furnishes methods to exploit the ability of lentiviral vectors to transduce both mitotically active and inactive cells so that eye diseases may be treated.
Owner:RES DEVMENT FOUND
Chemokine inhibition of immunodeficiency virus
InactiveUS6428970B2Organic active ingredientsPeptide/protein ingredientsImmunodeficiency virusViral infection
The invention relates to therapeutic compositions and methods for treating and preventing infection by an immunodeficiency virus, particularly HIV infection, using chemokine proteins, nucleic acids and / or derivatives or analogs thereof.
Owner:UNIV OF MARYLAND BALTIMORE
Compositions and methods of promoting wound healing
InactiveUS20100272679A1Promote and accelerate wound healingReduces the formation of scarsChemokinesPeptide/protein ingredientsMedicineBone healing
A method of treating a wound in a subject includes administering directly to the wound or an area proximate the wound an amount of SDF-I effective to promote healing of the wound of the subject.
Owner:THE CLEVELAND CLINIC FOUND +1
Preparation and use of superior vaccines
This invention provides an isolated population of polynucleotides comprising or corresponding to at least one polynucleotide shown in Table 1 and their respective complements. It also provides a polynucleotide encoding a ligand or antibody or engineered protein that binds to a cell surface protein of an antigen presenting cell and wherein the polynucleotide comprises or corresponds to a polynucleotide shown in Table 1 or its complement. The invention further provides a polynucleotide that encodes a transcription factor and wherein the polynucleotide comprises or corresponds to a polynucleotide shown in Table 1 or its complement.
Owner:ROBERTS BRUCE L +1
MCP-1 splice variants and methods of using same
InactiveUS20070092484A1Inhibitory activityPeptide/protein ingredientsGenetic material ingredientsPolynucleotideImmunology
Owner:COMPUGEN
Cytotoxic conjugates comprising a chemokine receptor targeting agent
InactiveUS7166702B1Enhance and aid in survivalPrevent proliferationPolypeptide with localisation/targeting motifChemokinesPhagocyteDendritic cell
Owner:OSPREY PHARMA USA INC
Compounds and methods to inhibit or augment an inflammatory response
InactiveUS6989435B2Alter chemokine expressionSufficient sequence complementarityOrganic active ingredientsBacteriaStereochemistryPeptide analog
Owner:CAMBRIDGE ENTERPRISE LTD
Genetic engineering of macrophages for immunotherapy
ActiveUS20170087185A1Promote growthWide applicabilityAntibacterial agentsHydrolasesWhite blood cellTumor therapy
Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and / or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.
Owner:SEATTLE CHILDRENS HOSPITAL (DBA SEATTLE CHILDRENS RES INST)
Design of CXC chemokine analogs for the treatment of human diseases
InactiveUS20070160574A1Improve cell activityReduce cell viabilityChemokinesPeptide/protein ingredientsCXCL17CxC chemokine
Owner:CHEMOKINE THERAPEUTIC
High-affinity antagonists of elr-cxc chemokines
The present invention provides novel polypeptide sequences, methods for production thereof and uses thereof for novel ELR-CXC chemokine receptor agonists and antagonists.
Owner:UNIVERSITY OF SASKATCHEWAN
Eotaxin: an eosinophil chemoattractant
Disclosed is substantially pure eotaxin DNA sequence and eotaxin polypeptide, and methods of using such DNA and polypeptide to direct chemotaxis of eosinophils. Methods are provided for the treatment diseases and disorders such as inflammation and tumorigenesis.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
Rantes-derived peptides with anti-hiv activity
InactiveUS20060165650A1Low production costChemokinesPeptide/protein ingredientsAnti hiv activityViral infection
RANTES-derived peptides and the use thereof in the treatment of diseases in which RANTES receptor is involved, such as viral infections, particularly HIV infections, and inflammatory, allergic, degenerative, neoplastic or metastatic diseases.
Owner:PRIMM SRL
Methods of treating and diagnosing diabetes with cx3cr1 modulators
InactiveUS20060160076A1Peptide/protein ingredientsGenetic material ingredientsCX3CR1Insulin resistance
The present invention provides compositions and methods for diagnosing and treating diabetes and insulin resistance. In particular, the invention provides methods of identifying modulators of CX3CR1 and using those modulators to treat diabetes, as well as methods of diagnosing diabetes by measuring the levels of CX3CR1 or fractalkine in a patient.
Owner:MEATABOLEX
CXCR4 antagonist treatment of hematopoietic cells
InactiveUS7435718B2Increase loopAvoid consumptionGenetic material ingredientsTetrapeptide ingredientsProgenitorCXCR4
In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem / progenitor cell multiplication / self-renewal.
Owner:CHEMOKINE THERAPEUTIC +1
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
Owner:OSPREY PHARMA USA
Methods of mesenchymal stem cell mobilization and expansion
A method of obtaining mesenchymal stem cells is provided. The method comprising:(a) administering to a subject an effective amount of a CXCR4 antagonistic peptide as set forth in SEQ ID NO: 1 so as to mobilize the mesenchymal stem cells to peripheral blood of the subject;(b) collecting the mesenchymal stem cells from the peripheral blood; and subsequently or concomitantly(c) purifying the mesenchymal stem cells using a mesenchymal stem cell-specific phenotype.
Owner:BIOKINE THERAPEUTICS LTD +1
Human interleukin II mutant and application thereof
The invention discloses a human interleukin II mutant and an application of the human interleukin II mutant in preparation of medicines. Mutation happens to a joint of an alpha acceptor and / or a beta acceptor and an amino acid sequence of human interleukin II protobiont, and the affinity of the human interleukin II to the alpha acceptor is reduced, thus the function of inducing regulatory T cells is reduced, the side effect that pulmonary edema can be caused can be reduced, the affinity to the beta acceptor is enhanced, and the attributes of the human interleukin II for natural killer cell immune activity are retained. The human interleukin II mutant can be used for stimulating an immune system and the function of inhibiting tumor growth is enhanced, thereby improving the clinical curative effect and application range.
Owner:SHANGHAI BIOMED UNION BIOTECHNOLOGY CO LTD
Peptides and compounds that bind to a receptor
Owner:SMITHKLINE BECKMAN CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com